Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Among authors: marquard j. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
Tamborlane WV, Laffel LM, Weill J, Gordat M, Neubacher D, Retlich S, Hettema W, Hoesl CE, Kaspers S, Marquard J. Tamborlane WV, et al. Among authors: marquard j. Pediatr Diabetes. 2018 Jun;19(4):640-648. doi: 10.1111/pedi.12616. Epub 2017 Nov 24. Pediatr Diabetes. 2018. PMID: 29171139 Clinical Trial.
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA. Rosenstock J, et al. Among authors: marquard j. Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4. Diabetes Care. 2018. PMID: 30287422 Clinical Trial.
Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
Laffel LMB, Tamborlane WV, Yver A, Simons G, Wu J, Nock V, Hobson D, Hughan KS, Kaspers S, Marquard J. Laffel LMB, et al. Among authors: marquard j. Diabet Med. 2018 Aug;35(8):1096-1104. doi: 10.1111/dme.13629. Epub 2018 May 6. Diabet Med. 2018. PMID: 29655290 Free PMC article. Clinical Trial.
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Perkins BA, Soleymanlou N, Rosenstock J, Skyler JS, Laffel LM, Liesenfeld KH, Neubacher D, Riggs MM, Johnston CK, Eudy-Byrne RJ, Elmokadem A, George JT, Marquard J, Nock V. Perkins BA, et al. Among authors: marquard j. Diabetes Obes Metab. 2020 Mar;22(3):427-433. doi: 10.1111/dom.13945. Epub 2020 Jan 21. Diabetes Obes Metab. 2020. PMID: 31858718 Free PMC article.
Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N. Cherney DZI, et al. Among authors: marquard j. Clin J Am Soc Nephrol. 2021 Nov;16(11):1715-1719. doi: 10.2215/CJN.07700621. Epub 2021 Sep 17. Clin J Am Soc Nephrol. 2021. PMID: 34535454 Free PMC article. No abstract available.
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Perkins BA, Rosenstock J, Skyler JS, Laffel LM, Cherney DZ, Mathieu C, Pang C, Wood R, Kinduryte O, George JT, Marquard J, Soleymanlou N. Perkins BA, et al. Among authors: marquard j. Diabetes Care. 2019 Sep;42(9):1716-1723. doi: 10.2337/dc19-0548. Epub 2019 Jun 8. Diabetes Care. 2019. PMID: 31177179 Free PMC article.
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina A, Shiki K, George J, Soleymanlou N, Marquard J. Shimada A, et al. Among authors: marquard j. Diabetes Obes Metab. 2018 Sep;20(9):2190-2199. doi: 10.1111/dom.13351. Epub 2018 Jun 5. Diabetes Obes Metab. 2018. PMID: 29766633 Free PMC article. Clinical Trial.
Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop.
Barrett JS, Bucci-Rechtweg C, Amy Cheung SY, Gamalo-Siebers M, Haertter S, Karres J, Marquard J, Mulugeta Y, Ollivier C, Strougo A, Yanoff L, Yao L, Zeitler P. Barrett JS, et al. Among authors: marquard j. Clin Pharmacol Ther. 2020 Jul;108(1):29-39. doi: 10.1002/cpt.1805. Epub 2020 Mar 16. Clin Pharmacol Ther. 2020. PMID: 32017043 Free PMC article.
105 results